Development and validation of a novel clinical decision support tool for sustained remission in Crohn’s disease: a multi-center real-world study

Scandinavian Journal of Gastroenterology 2026

View at publisher
Authors: Yun Qiu, Chuhan Zhang, Kang Chao, Lingjie Huang, Zicheng Huang, Pingxin Zhang, Xingrun Liu, Qian Cao, Xiang Gao, Minhu Chen
DOI: 10.1080/00365521.2025.2604779
Cited by: 0
References: 20

Abstract

BACKGROUND AND AIMS: Long-term outcomes for Crohn's disease (CD) patients treated with infliximab (IFX) remain suboptimal. We developed and validated a clinical decision support tool (CDST) to predict sustained remission in CD patients treated with infliximab (IFX). METHODS: = 367). RESULTS: CDST categorized patients into low- (25) groups. A cutoff of 25 points predicted 2-year CREM with 60% (95%CI 53.2%-66.5%) sensitivity and 52% (95% CI 41.2%-1.8%) specificity. CONCLUSIONS: We developed and validated a CDST to identify CD patients likely to achieve sustained remission on IFX therapy. By stratifying patients into distinct risk profiles, it guides personalized therapy initiation and monitoring.

Fields of Study & Subjects

Inflammatory Bowel Disease Rheumatoid Arthritis Research and Therapies Pregnancy and Medication Impact

Publication details

Journal / source
Scandinavian Journal of Gastroenterology
Publisher
Informa UK Limited
Volume
61
Issue
2
Pages
182–191
Publication date
2 January 2026
Language
EN